Improving vaccine trials in infectious disease emergencies

Marc Lipsitch, Nir Eyal

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Unprecedented global effort is under way to facilitate the testing of countermeasures in infectious disease emergencies. Better understanding of the various options for trial design is needed in advance of outbreaks, as is preliminary global agreement on the most suitable designs for the various scenarios. What would enhance the speed, validity, and ethics of clinical studies of such countermeasures? Focusing on studies of vaccine efficacy and effectiveness in emergencies, we highlight three needs: for formal randomized trials—even in most emergencies; for individually randomized trials—even in many emergencies; and for six areas of innovation in trial methodology. These needs should inform current updates of protocols and roadmaps.

Original languageEnglish (US)
Pages (from-to)153-156
Number of pages4
JournalScience
Volume357
Issue number6347
DOIs
StatePublished - Jul 14 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Improving vaccine trials in infectious disease emergencies'. Together they form a unique fingerprint.

Cite this